Alkami Technology

Company ALKT

Last mentioned: Feb 27, 2026

Timeline

  1. Q4 Earnings Call

    ACADIA reports strong year-end results and 2026 guidance.

  2. Daybue Stix Launch

    Launch of the granule formulation to enhance patient compliance.

  3. Daybue Approval

    FDA approves Daybue as the first treatment for Rett syndrome.

  4. Nuplazid Approval

    FDA approves Nuplazid for Parkinson's disease psychosis.

Stories mentioning Alkami Technology 1

pharma Neutral

ACADIA Pharmaceuticals Solidifies Rare Disease Leadership in Q4 Results

ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.

2 sources